Bank of Nova Scotia
PCRX icon

Bank of Nova Scotia’s Pacira BioSciences PCRX Stock Holding History

Bank of Nova Scotia’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-140,000
Closed -$6.38M – 974
2017
Q1 		$6.38M Sell
140,000
-358,000
-72% -$15.5M 0.03% 357
2016
Q4 		$16.1M Buy
+498,000
New +$16.6M 0.08% 156

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of Nova Scotia's PCRX Position: Q2 2017 in Review

Bank of Nova Scotia sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 140,000 shares — an estimated $6.38M sold.

Bank of Nova Scotia first reported a position in PCRX in Q4 2016 and held it in 2 quarters. The position peaked at $16.1M in Q4 2016. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Bank of Nova Scotia reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Bank of Nova Scotia sold 140,000 Pacira BioSciences shares in Q2 2017, an estimated $6.38M.
  • Bank of Nova Scotia first reported a position in Pacira BioSciences in Q4 2016 and held it in 2 quarters.
  • Bank of Nova Scotia's Pacira BioSciences position peaked at $16.1M in Q4 2016.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Bank of Nova Scotia's 13F filing for Q2 2017, filed 15 Aug 2017.